With a market cap of $52.1 billion, Edwards Lifesciences Corporation (EW) is a global leader in structural heart innovation, dedicated to improving patient lives through breakthrough medical technologies and evidence-based solutions. Driven by a patient-focused culture and strong partnerships with clinicians and healthcare stakeholders, the company delivers life-changing innovations to people around the world.
The Irvine, California-based company is expected to unveil its fiscal Q2 2026 results soon. Ahead of the event, analysts forecast EW to post an adjusted EPS of $0.73, a growth of nearly 9% from $0.67 in the same quarter last year. It has surpassed Wall Street's bottom-line projections in three of the past four quarters while missing on another occasion.